The general practitioner pharmacotherapy prescribing workforce: examining sustainability from a systems perspective

References

• Breen C, Degenhardt L, Roxburgh A, et al. Australian drug trends 2003. Findings from the illicit drug reporting system (IDRS). National Drug Research Institute, Sydney 2004
   Google Scholar
• Hall W, Ross J, Lynskey M, Law M, Degenhardt L. How many dependent opioid users are there in Australia?. National Drug and Alcohol Research Centre, Sydney 2000, Monograph no. 44
   Google Scholar
• Degenhardt L, Rendle V, Hall W, Gilmour S, Law M. Estimating the number of current regular heroin users in NSW and Australia 1997–2002. National Drug Research Institute, University of New South Wales, Sydney 2004, Technical report no. 198
   Google Scholar
• Roche A M, Evans K R. Harm reduction as a response to illicit drug use. Illicit drugs and Australian democracy: the search for new directions, G Stokes, P Chalk, K Gillen. Melbourne University Press, Melbourne 2000; 149–162
   Google Scholar
• Roche A M, Evans K R, Stanton W R. Harm reduction: roads less travelled to the Holy Grail. Addiction 1997; 92: 1207–1212
   PubMed Web of Science ®Google Scholar
• Single E, Rohl T. National drug strategy: mapping the future. Ministerial Council on Drug Strategy, Canberra 1997
   Google Scholar
• Loxley W. Doing the possible: harm reduction, injecting drug use and blood borne viral infections in Australia. Int J Drug Policy 2000; 11: 407–416
   PubMedGoogle Scholar
• Darke S. Injecting drug users and the human immunodeficiency virus: what do we know?. Drug Alcohol Rev 1992; 11: 153–161
   PubMedGoogle Scholar
• Marsch L. The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behaviour and criminality: a meta-analysis. Addiction 1998; 93: 515–532
   PubMed Web of Science ®Google Scholar
• Seivewright N, Iqbal M Z. Prescribing to drug misusers in practice—often effective, but rarely straightforward. Addict Biol 2002; 7: 269–277
   PubMed Web of Science ®Google Scholar
• Gossop M, Stewart D, Browne N, Marsden J. Methadone treatment for opiate dependent patients in general practice and specialist clinic settings: outcomes at a 2-year follow-up. J Subst Abuse Treat 2003; 24: 313–321
   PubMed Web of Science ®Google Scholar
• Penrose-Wall J, Copeland J, Harris M. Shared care of illicit drug problems by general practitioners and primary health care providers: a literature review. Centre for General Practice Integration Studies, National Drug and Alcohol Research Centre and South Western Sydney Area Health Service, Sydney 2000
   Google Scholar
• Darke S, Hall W, Topp L. The Illicit Drug Reporting System (IDRS) history and development of a national strategic early warning system for monitoring trends in illicit drug use. National Drug and Alcohol Research Centre, Sydney 2000
   Google Scholar
• Kutin J, Lintzeris N, Ezard N, Mulheisen P. Evaluation of the specialist methadone service. Autumn School of Studies on Alcohol and Drugs. St Vincent's Hospital, Melbourne 1996; 97–104
   Google Scholar
• Ali R. Personal communication, (14 February 2002)
   Google Scholar
• Bell J. Quality improvement for methadone maintenance treatment. Subst Use Misuse 2000; 35: 1735–1736
   PubMed Web of Science ®Google Scholar
• Bell J. Delivering effective methadone treatment. Methadone maintenance treatment, J Ward, R Mattick, W Hall. Harwood Academic Publishers, Amsterdam 1998; 161–175
   Google Scholar
• Weinrich M, Stuart M. Provision of methadone treatment in primary care medical practices. Review of the Scottish experience and implications for US policy. JAMA 2000; 283: 1343–1348
   PubMed Web of Science ®Google Scholar
• Bell J. Training health professionals to deliver methadone treatment. Methadone maintenance treatment and opioid replacement therapies, J Ward, R Mattick, W Hall. Harwood Academic Publishers, Amsterdam 1998; 361–378
   Google Scholar
• Gruer L, Wilson P G, Scott R, et al. General practitioner centred scheme for treatment of opiate dependent drug injectors in Glasgow. BMJ 1997; 314: 1730
   PubMed Web of Science ®Google Scholar
• Parker J, Gay M. Problem drug users known to Bristol medical practitioners. J R Coll Gen Pract 1987; 260–263
   PubMedGoogle Scholar
• Tantam D, Donmall M, Webster A, Strang J. Do general practitioners and general psychiatrists want to look after drug misusers? Evaluation of a non-specialist treatment policy. Br J Gen Pract 1993; 43: 470–474
   PubMed Web of Science ®Google Scholar
• Sheridan J, Strang J, Taylor N, Barber N. HIV Prevention and drug treatment services for drug misusers: a national study of community pharmacists' attitudes and their involvement in training. Addiction 1997; 92: 1737–1748
   PubMed Web of Science ®Google Scholar
• McNeely J, Drucker E, Hartel D, Tuchman E. Office-based methadone prescribing: acceptance by inner-city practitioners in New York. J Urban Health: Bull NY Acad Med 2000; 77: 96–102
   PubMed Web of Science ®Google Scholar
• Roche A, Watt K, Fischer J. General practitioners' views of home detoxification. Drug Alcohol Rev 2001; 20: 395–406
   Web of Science ®Google Scholar
• Roche A, Hotham E D, Richmond R L. The general practitioner's role in AOD issues: overcoming individual, professional and systemic barriers. Drug Alcohol Rev 2002; 21: 223–230
   PubMed Web of Science ®Google Scholar
• Ministerial Council on Drug Strategy. The national drug strategy. Australia's Integrated Framework 2004–2009. Australian Government, Canberra June, 2004
   Google Scholar
• Australian Health Ministers' Conference. National Health Workforce Action Plan. 2004, [online: cited 30 August 2004]. Available at: http://www.health.nsw.gov.au/amwac/pdf/NHW_action_plan.pdf
   Google Scholar
• Joyce C M, McNeil J J, Stoelwinder J U. Time for a new approach to medical workforce planning. Med J Aust 2004; 180: 343–346
   PubMed Web of Science ®Google Scholar
• Ali R, Allsop S, Bell J, et al. National learning objectives and assessment procedures for the pharmacological management of opioid dependence. Australian Government Department of Health and Ageing (National Drug Strategy), Canberra 2004
   Google Scholar